###begin article-title 0
###xml 12 15 12 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox</italic>
###xml 18 27 18 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pu&#916;tk</italic>
Bigenic Cre/loxP, puDeltatk conditional genetic ablation
###end article-title 0
###begin p 1
###xml 95 116 95 116 <email xmlns:xlink="http://www.w3.org/1999/xlink">abradley@sanger.ac.uk</email>
To whom correspondence should be addressed. Tel: +44 1223 494881; Fax: +44 1223 494714; Email: abradley@sanger.ac.uk
###end p 1
###begin p 2
###xml 90 97 90 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 230 239 230 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pu&#916;tk</italic>
###xml 453 460 449 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col2Cre</italic>
###xml 747 756 743 748 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pu&#916;tk</italic>
###xml 795 798 787 790 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cre</italic>
###xml 203 208 <span type="species:ncbi:10090">mouse</span>
Genetic ablation experiments are used to resolve problems regarding cell lineages and the in vivo function of certain groups of cells. We describe a two-component conditional ablation technology using a mouse carrying an X-linked puDeltatk transgene, which is only activated in cells expressing Cre. Ablation of the Cre-expressing cells can be temporally regulated by the time of ganciclovir (GCV) administration. This strategy was demonstrated using a Col2Cre transgenic line. Differentiating chondrocytes in bigenic animals could be ablated at different developmental stages resulting in disorganized growth plates and dwarfism. Macrocephaly, macroglossia and umbilical hernia were also observed in ablated 18.5 dpc embryos. Crosses between the puDeltatk selector transgenic line and existing cre lines will facilitate numerous temporally regulated tissue-specific ablation experiments.
###end p 2
###begin title 3
INTRODUCTION
###end title 3
###begin p 4
###xml 173 174 173 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c1">1</xref>
###xml 175 176 175 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c3">3</xref>
###xml 235 242 235 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 347 348 347 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c4">4</xref>
###xml 349 350 349 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c5">5</xref>
###xml 490 512 490 512 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Caenorhabditis elegans</italic>
###xml 514 515 514 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c6">6</xref>
###xml 673 674 673 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c1">1</xref>
###xml 675 676 675 676 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c7">7</xref>
###xml 677 678 677 678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c8">8</xref>
###xml 881 882 881 882 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c2">2</xref>
###xml 883 884 883 884 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c9">9</xref>
###xml 490 512 <span type="species:ncbi:6239">Caenorhabditis elegans</span>
Cell ablation experiments are used to resolve questions regarding cell lineages, physiological function, differentiation potential and interactions between groups of cells (1-3). Different strategies have been used to achieve ablation in vivo. Surgical ablation can be used to remove a specific organ or an embryonic precursor during development (4,5). Laser surgery can be used to ablate single cells in organisms with well-defined cell lineages and with a limited number of cells such as Caenorhabditis elegans (6). Ablation can also be achieved genetically, based on the temporal and spatial expression pattern of a transgene in a group of cells in a transgenic animal (1,7,8). Genetic ablation targeted by the expression of molecular markers can be more precise than surgical techniques, because molecular differences between adjacent cells are often not obvious anatomically (2,9).
###end p 4
###begin p 5
###xml 137 157 137 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Herpes Simplex Virus</italic>
###xml 165 181 165 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">thymidine kinase</italic>
###xml 188 190 188 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tk</italic>
###xml 193 194 193 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c1">1</xref>
###xml 195 196 195 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c3">3</xref>
###xml 197 198 197 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c9">9</xref>
###xml 435 436 435 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c3">3</xref>
###xml 437 439 437 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c10">10</xref>
###xml 452 454 452 454 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tk</italic>
###xml 627 628 627 628 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d</sc>
###xml 822 823 822 823 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c1">1</xref>
###xml 824 825 824 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c8">8</xref>
###xml 859 861 859 861 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tk</italic>
###xml 943 945 943 945 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tk</italic>
###xml 947 949 947 949 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c11">11</xref>
###xml 950 952 950 952 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c13">13</xref>
###xml 20 35 <span type="species:ncbi:10090">transgenic mice</span>
###xml 183 187 <span type="species:ncbi:10298?0.9473684210526315">HSV1</span>
###xml 447 451 <span type="species:ncbi:10298?0.9473684210526315">HSV1</span>
###xml 854 858 <span type="species:ncbi:10298?0.9473684210526315">HSV1</span>
###xml 913 928 <span type="species:ncbi:10090">transgenic mice</span>
###xml 938 942 <span type="species:ncbi:10298?0.9473684210526315">HSV1</span>
Genetic ablation in transgenic mice utilizes tissue-specific promoters to drive suicide genes, such as diphtheria toxin A chain (DTA) or Herpes Simplex Virus type I thymidine kinase (HSV1 tk) (1-3,9). When DTA is used, the cells in the target tissue are killed when DTA is expressed. Embryonic expression of DTA ablates cells and tissues during development which prevents analysis of target tissues in later development or adult life (3,10). When HSV1 tk is used, temporal control of the ablation is possible, because killing depends on the administration of a prodrug, such as ganciclovir (GCV) or 1-(-2-deoxy-2-fluoro-1-beta-d-arabino-furanosyl)-5-iodouracil (FIAU). Thus, ablation that causes embryonic or neonatal lethality can be avoided, enabling the physiological function of target cells to be examined in adults (1,8). Despite the advantages of HSV1 tk, its use is constrained by the infertility of male transgenic mice carrying HSV1 tk (11-13).
###end p 5
###begin p 6
###xml 35 44 35 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pu&#916;tk</italic>
###xml 130 139 126 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pu&#916;tk</italic>
###xml 189 190 177 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 241 243 229 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tk</italic>
###xml 303 305 291 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c14">14</xref>
###xml 312 321 300 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pu&#916;tk</italic>
###xml 384 387 368 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cre</italic>
###xml 575 582 559 566 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col2Cre</italic>
###xml 21 26 <span type="species:ncbi:10090">mouse</span>
###xml 236 240 <span type="species:ncbi:10298?0.9473684210526315">HSV1</span>
###xml 286 301 <span type="species:ncbi:10090">transgenic mice</span>
Here, we described a mouse strain, puDeltatk selector, which responds to Cre expression by activating a conditional suicide gene, puDeltatk. PuDeltatk is a fusion protein between puromycin N-acetyltransferase and a truncated version of HSV1 tk, which does not cause male infertility in transgenic mice (14). The puDeltatk selector allele can be used with the existing tissue-specific cre lines so that conditional cell ablation experiments can be performed in a variety of tissues. We demonstrate ablation at different developmental stages in both embryos and adults using a Col2Cre transgene.
###end p 6
###begin title 7
MATERIALS AND METHODS
###end title 7
###begin title 8
###xml 0 9 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pu&#916;tk</italic>
puDeltatk selector construction
###end title 8
###begin p 9
###xml 13 16 13 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox</italic>
###xml 215 218 215 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox</italic>
###xml 593 596 593 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neo</italic>
###xml 750 753 750 753 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox</italic>
###xml 766 774 766 774 <italic xmlns:xlink="http://www.w3.org/1999/xlink">loxP-neo</italic>
###xml 779 783 779 783 <italic xmlns:xlink="http://www.w3.org/1999/xlink">loxP</italic>
###xml 855 857 855 857 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c14">14</xref>
###xml 968 977 968 973 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pu&#916;tk</italic>
###xml 1028 1036 1024 1032 <italic xmlns:xlink="http://www.w3.org/1999/xlink">loxP-neo</italic>
###xml 1041 1055 1037 1047 <italic xmlns:xlink="http://www.w3.org/1999/xlink">loxP-pu&#916;tk</italic>
###xml 1064 1068 1056 1060 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hprt</italic>
###xml 1146 1150 1138 1142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hprt</italic>
###xml 1164 1168 1156 1160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hprt</italic>
###xml 1187 1189 1179 1181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c15">15</xref>
###xml 1275 1278 1267 1270 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox</italic>
###xml 1356 1372 1348 1364 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Escherichia coli</italic>
###xml 620 626 <span type="species:ncbi:9913">bovine</span>
###xml 1356 1372 <span type="species:ncbi:562">Escherichia coli</span>
Two adjacent loxP sites were inserted into pBSII-KS- by a three-way ligation between a PstI and XhoI double digested pBSII-KS- plasmid and two small DNA fragments composed of two sets of oligonucleotides containing loxP sites as well as an AscI site or an SfiI site. 3295 5'-GGG GGG CCG ATC AGG CCA TAA CTT CGT ATA GCA TAC ATT ATA CGA AGT TAT C-3', 3296 5'-TCG AGA TAA CTT CGT ATA ATG TAT GCT ATA CGA AGT TAT GGC CTG ATC GGC C-3', 3297 5'-GAT AAC TTC GTA TAG CAT ACA TTA TAC GAA GTT ATG GCG CGC C-3', 3298 5'-CCC CGG CGC GCC ATA ACT TCG TAT AAT GTA TGC TAT ACG AAG TTA TCT GCA-3'. A neomycin (neo) coding region and the bovine growth hormone poly(A) signal (bpA) was then introduced between the AscI and SfiI sites, so that it was flanked by the two loxP sites. The loxP-neo-bpA-loxP cassette was then excised from this vector and inserted into a pYTC37 (14) derived plasmid in a position downstream of the phosphoglycerate kinase-1 promoter (PGK) and upstream of the puDeltatk coding region to create the selector cassette PGK-loxP-neo-bpA-loxP-puDeltatk-bpA. An Hprt replacement targeting vector was constructed by inserting this cassette into Hprt exon 3 of an Hprt targeting vector (15) in an orientation opposite to that of endogenous transcription. The function of the loxP sites in this vector were tested by transforming constructs into the BNN132 Escherichia coli strain (BD Biosciences Clontech, CA).
###end p 9
###begin title 10
###xml 14 23 14 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pu&#916;tk</italic>
###xml 33 37 <span type="species:ncbi:10090">mice</span>
Generation of puDeltatk selector mice
###end title 10
###begin p 11
###xml 137 139 137 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c16">16</xref>
###xml 140 142 140 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c17">17</xref>
###xml 452 454 452 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c15">15</xref>
###xml 482 485 482 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox</italic>
###xml 500 509 500 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pu&#916;tk</italic>
###xml 647 650 643 646 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cre</italic>
###xml 676 690 672 682 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hprt pu&#916;tk</italic>
###xml 643 646 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 726 730 <span type="species:ncbi:10090">mice</span>
The targeting construct was linearized with PvuI and electroporated into the AB1 ES cell line maintained on irradiated SNLP-7/4 feeders (16,17). G418 selection was initiated 24 h after electroporation and maintained for 4 days. Subsequently, the cells were selected in both G418 and 6-thioguanine for 6 days. Targeted clones were picked and confirmed by Southern blot analysis of HindIII-digested genomic DNA, probed with an external genomic fragment (15). The functionality of the loxP sites in the puDeltatk selector ES cell line was tested by the acquisition of both puromycin resistance and FIAU sensitivity following electroporation of a CMV-cre expression cassette. The Hprt puDeltatk selector allele was established in mice following blastocyst injection and germ line transmission of the BC85-D4 clone.
###end p 11
###begin title 12
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice
###end title 12
###begin p 13
###xml 13 22 13 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pu&#916;tk</italic>
###xml 56 63 52 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col2Cre</italic>
###xml 84 86 80 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c18">18</xref>
###xml 100 107 96 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col2Cre</italic>
###xml 109 118 105 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pu&#916;tk</italic>
###xml 296 305 288 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pu&#916;tk</italic>
###xml 315 319 <span type="species:ncbi:10090">mice</span>
Heterozygous puDeltatk selector females were mated with Col2Cre heterozygous males (18) to generate Col2Cre, puDeltatk progeny. GCV (Roche, CA) was administered daily at a dose of 100 mg/kg by intraperitoneal injection. For embryonic chondrocyte ablation, GCV was administered to pregnant female puDeltatk selector mice beginning either at 4.5 dpc, 12.5 dpc or 14.5 dpc and repeated daily until 18.5 dpc. For adult chondrocyte ablation, GCV was administered daily to 2-week-old pups for either 3 or 6 weeks.
###end p 13
###begin title 14
RT-PCR
###end title 14
###begin p 15
###xml 36 43 36 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col2Cre</italic>
###xml 45 54 45 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pu&#916;tk</italic>
###xml 393 402 386 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pu&#916;tk</italic>
###xml 449 458 435 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pu&#916;tk</italic>
Dissected tissues from a 2-week-old Col2Cre, puDeltatk compound heterozygous male were frozen in liquid nitrogen. Total RNA was extracted using Trizol (Invitrogen, CA) and reverse transcribed by MMLV reverse transcriptase (Superscript II; Invitrogen). Primers used for reverse transcription are either poly(T) for beta-actin or 5893 5'-GCT CTA GAG CTC AGT TAG CCT CCC CCA TCT CCC GGG C-3' for puDeltatk. Primers for PCR reactions for beta-actin and puDeltatk were 5641 5'-GAG AAG AGC TAT GAG CTG CCT-3', 5642 5'-TTC TGC ATC CTG TCA GCA ATG-3', 5891 5'-ATG ACA AGC GCC CAG ATA AC -3' and 5892 5'-ATG CTG CCC ATA AGG TAT CG -3'.
###end p 15
###begin title 16
BrdU labelling
###end title 16
###begin p 17
###xml 289 291 287 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c19">19</xref>
###xml 14 18 <span type="species:ncbi:10090">mice</span>
###xml 697 701 <span type="species:ncbi:10090">mice</span>
Five-week-old mice were injected intraperitoneally with 100 mul of 100 muM Bromodeoxyuridine (BrdU) (Sigma, St. Louis, MO) in phosphate-buffered saline 1 h before the tibia was isolated. The tibia was fixed for 6 h in 4% paraformaldehyde (PFA) (Sigma) and processed for paraffin sections (19). Seven micrometer sections were prepared and BrdU incorporation was visualized using a staining kit (Zymed, CA). Equivalent sections were selected and BrdU positive cells were counted in the same regions from all genotypes. This data was expressed as a percentage of the total number of chondrocytes in the proliferating zone or the extended 'hypertrophic chondrocyte-like' region in the ablated bigenic mice.
###end p 17
###begin title 18
X-ray analysis
###end title 18
###begin p 19
###xml 144 148 <span type="species:ncbi:10090">mice</span>
X-ray analysis was performed using a Faxitron Specimen Radiography System Model MX-20 (Faxitron, IL). Before analysis the skin was removed, the mice were eviscerated and fixed in PFA.
###end p 19
###begin title 20
Morphometry and histology
###end title 20
###begin p 21
###xml 248 250 248 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c20">20</xref>
###xml 629 631 628 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c21">21</xref>
###xml 632 634 631 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c22">22</xref>
Femur length measurements were performed on cleaned bones with a dial caliper (Scienceware, NJ). For histological analysis, tibias were fixed in 4% PFA overnight, dehydrated in graded ethanols and embedded in methyl methacylate at low temperature (20). Sagital 7 mum sections of the calcified tibia were cut with a tungsten carbide blade and collected on precoated slides (Superfrost Plus, NH). Sections were stained according to the Von Kossa method with a Van Gieson counterstain to analyse mineralized and osteoid bone. They were also stained with Weigert's haematoxilin/fast green/safranin O for bone and cartilage analysis (21,22).
###end p 21
###begin title 22
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In situ</italic>
In situ hybridization
###end title 22
###begin p 23
###xml 50 60 50 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col2&#945;1</italic>
###xml 62 81 58 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col10&#945;1 in situ</italic>
###xml 138 140 130 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c23">23</xref>
###xml 141 143 133 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c24">24</xref>
###xml 391 393 376 378 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 448 458 433 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col2&#945;1</italic>
###xml 463 474 444 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col10&#945;1</italic>
###xml 485 487 462 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c24">24</xref>
###xml 606 616 577 583 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col2&#945;1</italic>
###xml 643 654 610 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col10&#945;1</italic>
Sample preparations for paraffin sections and the Col2alpha1, Col10alpha1 in situ hybridization were carried out as described previously (23,24). Briefly, dissected tibias were fixed in 4% PFA overnight and decalcified in EDTA (pH 7.4) for 10 days at 4degreesC prior to embedding in paraffin. Paraffin sections (7 mum) were collected on acid-etched, TESPA-treated slides. Sense or antisense 35S-labelled riboprobes were transcribed from linearized Col2alpha1 and Col10alpha1 plasmids (24). Slides were washed at a final stringency of 65degreesC in 2x SSC, dipped in emulsion and exposed for 1 week for the Col2alpha1 probe and 2 weeks for the Col10alpha1 probe. The developed slides were counterstained with Hoechst 33342.
###end p 23
###begin title 24
Skeleton preparations
###end title 24
###begin p 25
###xml 221 223 221 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c25">25</xref>
Embryos at 18.5 dpc were dissected from the uteri. The skin was removed, the carcasses were eviscerated, fixed in 95% ethanol, stained with Alizarin Red S and Alcian Blue, cleared by KOH treatment and stored in glycerol (25).
###end p 25
###begin title 26
RESULTS AND DISCUSSION
###end title 26
###begin title 27
###xml 20 29 20 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pu&#916;tk</italic>
###xml 39 44 <span type="species:ncbi:10090">mouse</span>
Construction of the puDeltatk selector mouse
###end title 27
###begin p 28
###xml 58 61 58 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cre</italic>
###xml 203 212 203 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pu&#916;tk</italic>
###xml 221 222 217 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gnh158f1">1</xref>
###xml 226 235 222 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pu&#916;tk</italic>
###xml 341 343 333 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tk</italic>
###xml 345 347 337 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c14">14</xref>
###xml 354 363 346 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pu&#916;tk</italic>
###xml 485 487 473 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c26">26</xref>
###xml 696 698 684 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c27">27</xref>
###xml 751 754 739 742 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox</italic>
###xml 764 767 752 755 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neo</italic>
###xml 827 830 815 818 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox</italic>
###xml 850 853 838 841 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neo</italic>
###xml 902 911 890 895 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pu&#916;tk</italic>
###xml 969 978 953 958 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pu&#916;tk</italic>
###xml 997 1006 977 982 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pu&#916;tk</italic>
###xml 1181 1189 1157 1165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 1203 1212 1179 1184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pu&#916;tk</italic>
###xml 1266 1268 1238 1240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c28">28</xref>
###xml 299 314 <span type="species:ncbi:10090">transgenic mice</span>
###xml 336 340 <span type="species:ncbi:10298?0.9473684210526315">HSV1</span>
###xml 679 694 <span type="species:ncbi:10090">transgenic mice</span>
To generate an allele which can be combined with existing cre lines to initiate ablation in different tissues, we constructed a cassette which responds to Cre by activating the conditional suicide gene, puDeltatk (Figure 1A). puDeltatk avoids the complication of male infertility frequently seen in transgenic mice carrying full-length HSV1 tk (14). The puDeltatk selector construct is driven by the PGK promoter which has a broad expression pattern at different developmental stages (26). It was shown that the PGK promoter can drive ubiquitous expression of a reporter gene in many embryonic organs, including the liver, kidney, intestine, heart, limb and rib cartilage in the transgenic mice (27). In an un-induced state, the PGK promoter drives a loxP flanked neo cassette. When Cre is expressed, recombination between the loxP sites deletes the neo-bpA cassette, resulting in juxtaposition of the puDeltatk cassette and the PGK promoter resulting in expression of puDeltatk. The suicide gene puDeltatk is only activated in cells which express Cre and their descendants. These cells can be killed by prodrugs, such as GCV or FIAU. These same cell lineages can also be selected in vitro, because the puDeltatk fusion gene enables positive selection in puromycin (28).
###end p 28
###begin p 29
###xml 4 13 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pu&#916;tk</italic>
###xml 56 60 52 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hprt</italic>
###xml 94 95 90 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gnh158f1">1</xref>
###xml 248 252 244 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hprt</italic>
###xml 291 293 287 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c29">29</xref>
###xml 294 296 290 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c31">31</xref>
###xml 319 328 315 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pu&#916;tk</italic>
###xml 258 262 <span type="species:ncbi:10090">mice</span>
###xml 396 400 <span type="species:ncbi:10090">mice</span>
The puDeltatk cassette was targeted into the endogenous Hprt gene on the X-chromosome (Figure 1A and B). This locus is an excellent site for inserting transgenes, because a single copy transgene can be easily targeted to this locus in ES cells and Hprt null mice have a very mild phenotype (29-31). The location of the puDeltatk construct on the X-chromosome enables this allele to be tracked in mice, reducing the need for molecular genotyping. X-inactivation in females allows partial ablation experiments to be conducted in situations where the ablated cell type is essential for survival, while complete ablation can be achieved in males.
###end p 29
###begin p 30
###xml 13 22 13 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pu&#916;tk</italic>
###xml 185 194 181 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pu&#916;tk</italic>
###xml 322 331 314 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pu&#916;tk</italic>
###xml 513 517 501 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hprt</italic>
###xml 579 588 567 572 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pu&#916;tk</italic>
###xml 599 601 583 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c14">14</xref>
###xml 602 604 586 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c31">31</xref>
###xml 530 534 <span type="species:ncbi:10090">mice</span>
###xml 561 565 <span type="species:ncbi:10090">mice</span>
The targeted puDeltatk selector ES cell line BC85-D4 was tested for its response to Cre following transient expression. The clone BC85-D4 was used to establish germ line chimaeras. The puDeltatk selector allele was only found in the female descendents from transmitting chimaeras consistent with its X-linkage. Hemizygous puDeltatk selector males were obtained in the next generation, and these did not show any overt phenotype and their fertility was normal. This is consistent with the previous observations of Hprt null mutant mice and the fertility of male mice carrying the puDeltatk cassette (14,31).
###end p 30
###begin title 31
GCV killing of proliferating chondrocytes
###end title 31
###begin p 32
###xml 33 42 33 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pu&#916;tk</italic>
###xml 88 95 84 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 137 146 133 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pu&#916;tk</italic>
###xml 202 209 194 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col2Cre</italic>
###xml 234 235 226 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gnh158f1">1</xref>
###xml 119 123 <span type="species:ncbi:10090">mice</span>
To test the effectiveness of the puDeltatk cassette in mediating Cre dependent ablation in vivo, compound heterozygous mice carrying the puDeltatk selector allele and chondrocyte-specific Cre cassette (Col2Cre) were generated (Figure 1C).
###end p 32
###begin p 33
###xml 13 22 13 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pu&#916;tk</italic>
###xml 69 76 65 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col2Cre</italic>
###xml 78 80 74 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c18">18</xref>
###xml 303 312 299 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pu&#916;tk</italic>
###xml 428 435 420 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col2Cre</italic>
###xml 437 446 429 434 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pu&#916;tk</italic>
###xml 460 461 448 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gnh158f2">2</xref>
Heterozygous puDeltatk selector females were crossed to heterozygous Col2Cre (18) males to generate progeny with all four possible genotypes. Owing to random X-inactivation, mosaic expression of the selector cassette is expected in females, and therefore only male progeny were used. Cartilage-specific puDeltatk mRNA expression was confirmed by RT-PCR performed on RNA samples isolated from different tissues from a 2-week-old Col2Cre, puDeltatk male (Figure 2A).
###end p 33
###begin p 34
###xml 187 194 187 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col2Cre</italic>
###xml 199 208 199 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pu&#916;tk</italic>
###xml 333 334 329 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gnh158f2">2</xref>
###xml 508 517 504 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pu&#916;tk</italic>
###xml 519 526 511 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col2Cre</italic>
###xml 565 566 557 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gnh158f2">2</xref>
###xml 218 222 <span type="species:ncbi:10090">mice</span>
###xml 610 614 <span type="species:ncbi:10090">mice</span>
###xml 779 783 <span type="species:ncbi:10090">mice</span>
Bigenic males were treated daily with GCV starting at 2 weeks of age. GCV-mediated killing of the proliferating chondrocytes was evaluated by BrdU incorporation at 5 weeks. In wild-type, Col2Cre and puDeltatk selector mice, 12-13% of the chondrocytes in the proliferating zone of the tibia growth plate were labelled by BrdU (Figure 2C). Thus, GCV treatment did not appear to affect proliferating chondrocytes. In contrast, no BrdU-labelled chondrocytes could be detected in tibia growth plate sections from puDeltatk, Col2Cre compound heterozygous animals (Figure 2C). These sections also revealed that these mice had disorganized growth plates with no proliferation zone. Thus, GCV treatment mediated complete killing of the proliferating chondrocytes in compound heterozygous mice.
###end p 34
###begin title 35
Proliferating chondrocyte ablation blocks long bone growth
###end title 35
###begin p 36
###xml 454 455 454 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gnh158f3">3</xref>
###xml 115 119 <span type="species:ncbi:10090">mice</span>
###xml 301 305 <span type="species:ncbi:10090">Mice</span>
###xml 418 422 <span type="species:ncbi:10090">mice</span>
###xml 595 599 <span type="species:ncbi:10090">mice</span>
The impact of proliferating chondrocyte ablation on long bone growth was analysed. All four different genotypes of mice were treated with GCV from 2 weeks of age and as early as 3 weeks after the initiation of GCV treatment the growth in length of the long bones in compound heterozygotes had ceased. Mice of the other three genotypes were unaffected (data not shown). Whole body X-ray photographs were taken when the mice reached 8 weeks of age (Figure 3A). These revealed dwarfism, reduced bone density, dome-shaped rib cages and bowing of the extremities in GCV-treated compound heterozygous mice. Where the growth plates ought to have been increased opacity was noted. Thus, GCV ablation of proliferating chondrocytes appeared to block long bone growth.
###end p 36
###begin p 37
###xml 65 72 65 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col2Cre</italic>
###xml 74 83 74 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pu&#916;tk</italic>
###xml 323 324 319 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gnh158f3">3</xref>
###xml 676 677 672 673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gnh158f3">3</xref>
###xml 84 88 <span type="species:ncbi:10090">mice</span>
Detailed analysis of Von Kossa stained sections from GCV-treated Col2Cre, puDeltatk mice revealed that both primary and secondary spongiosa were absent (data not shown) and that the growth plates were disorganized, with no obvious proliferating chondrocyte zone and an extended hypertrophic chondrocyte-like region (Figure 3C and D). Chondrocytes within the hypertrophic chondrocyte-like region were enlarged but did not appear to have undergone apoptosis. Blood vessel invasion was not observed, indicating that the long bone growth process was blocked. However, analysis of Von Kossa stained tibia sections indicated that the mineralization process was not affected (Figure 3C and D).
###end p 37
###begin title 38
Abnormal hypertrophic chondrocyte differentiation
###end title 38
###begin p 39
###xml 334 335 334 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gnh158f4">4</xref>
###xml 99 103 <span type="species:ncbi:10090">mice</span>
The extended hypertrophic chondrocyte-like region in the proliferating chondrocyte-ablated bigenic mice was examined in more detail. Tibia sections stained with safranin O, which stains cartilage matrix glycoprotein, showed that the cartilage matrix was relatively normal after the proliferating chondrocytes had been ablated (Figure 4).
###end p 39
###begin p 40
###xml 39 49 39 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col2&#945;1</italic>
###xml 82 93 78 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col10&#945;1</italic>
###xml 96 98 88 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c32">32</xref>
###xml 115 122 107 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ</italic>
###xml 169 179 161 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col2&#945;1</italic>
###xml 300 311 288 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col10&#945;1</italic>
###xml 730 732 714 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c32">32</xref>
###xml 733 735 717 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c33">33</xref>
###xml 927 928 911 912 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gnh158f3">3</xref>
###xml 938 949 922 929 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col10&#945;1</italic>
###xml 1070 1081 1050 1057 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col10&#945;1</italic>
###xml 1093 1095 1069 1071 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c34">34</xref>
###xml 1096 1098 1072 1074 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c35">35</xref>
###xml 1087 1091 <span type="species:ncbi:10090">mice</span>
Markers of proliferating chondrocytes (Col2alpha1) and hypertrophic chondrocytes (Col10alpha1) (32) were tested by in situ hybridization on tibia growth plate sections. Col2alpha1 transcripts were absent in the GCV-treated bigenic animals, indicating complete ablation of proliferating chondrocytes. Col10alpha1 transcripts were absent in the tibia growth plates of the GCV-treated bigenic animals, suggesting that the enlarged chondrocytes observed in the extended hypertrophic chondrocyte-like region are not terminally differentiated hypertrophic chondrocytes. One possible explanation for this phenotype is that proliferating chondrocytes are essential for the proper function or differentiation of hypertrophic chondrocytes (32,33), implicating signalling between proliferating and hypertrophic chondrocytes. Interestingly, normal mineralization was observed in the growth plate of the GCV-treated bigenic animals (Figure 3D). Thus, Col10alpha1 expression is not necessary for the mineralization process, consistent with the observation of normal mineralization in Col10alpha1 null mice (34,35).
###end p 40
###begin p 41
###xml 336 337 336 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gnh158f4">4</xref>
###xml 439 446 439 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ</italic>
###xml 489 499 489 495 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col2&#945;1</italic>
###xml 504 515 500 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col10&#945;1</italic>
The reversibility of GCV-mediated long bone growth block was examined. Drug treatment was stopped after 3 weeks of administration and tibias were isolated and examined 3 weeks later. The extended hypertrophic chondrocyte-like region in the growth plate was absent and replaced by a thinner growth plate with normal organization (Figure 4). The normal proliferating chondrocyte zone and the hypertrophic chondrocyte zone were restored, and in situ hybridization analysis revealed that both Col2alpha1 and Col10alpha1 expression patterns had returned to normal. Primary and secondary spongiosa was also observed in the tibia section after the recovery period. Thus, the GCV treatment did not kill or prevent resting chondrocytes from restoring a functional growth plate, and chondrocytes lying in the extended hypertrophic chondrocyte-like region were able to terminally differentiate into functional hypertrophic chondrocytes that could participate the long bone growth.
###end p 41
###begin title 42
Embryonic GCV-mediated chondrocyte ablation
###end title 42
###begin p 43
###xml 105 123 105 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pu&#916;tk selector</italic>
###xml 150 157 146 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col2Cre</italic>
###xml 388 390 384 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c36">36</xref>
To test whether this conditional ablation system can be used during development, GCV was administered to puDeltatk selector females after mating with Col2Cre males. Daily GCV treatment was initiated 1 day after implantation (4.5 dpc) and the embryos were examined at E18.5. The sex of embryos was assessed based on anatomic features and was confirmed using a Y-chromosome-specific probe (36).
###end p 43
###begin p 44
###xml 85 86 85 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gnh158f5">5</xref>
###xml 302 303 302 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gnh158f5">5</xref>
###xml 466 467 466 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gnh158f5">5</xref>
###xml 499 500 499 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gnh158f5">5</xref>
###xml 540 541 540 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gnh158f5">5</xref>
###xml 623 624 623 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gnh158f5">5</xref>
###xml 739 741 739 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c37">37</xref>
###xml 742 744 742 744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c39">39</xref>
###xml 685 690 <span type="species:ncbi:10090">mouse</span>
The GCV-treated bigenic 18.5 dpc embryos were smaller than their littermates (Figure 5A). On average, they were 70% of the normal length and 50% of the normal weight. They exhibited multiple cranial-facial defects and an abnormal skin texture. The GCV-treated bigenic embryos show macroglossia (Figure 5B and C), which is commonly seen in mutants that have defects in chondrocyte development. The GCV-treated bigenic animals also exhibit an umbilical hernia (Figure 5D and E), cleft palate, (Figure 5F) and under ossified vertebrae (Figure 5G, H and I). Dome-shaped heads and other head abnormalities were observed (Figure 5A, F and I). These features are reminiscent of those seen in mouse mutants with chondrocyte developmental defects (37-39).
###end p 44
###begin p 45
###xml 504 506 504 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c38">38</xref>
We explored the consequences of initiating ablation at different embryonic stages. GCV treatment was initiated at E4.5, E12.5 and E14.5, which gave different degrees of chondrocyte ablation. GCV treatment initiated at 4.5 dpc results in the most severe phenotype. There is almost no ossification seen in the ribs and vertebrae of these embryos. These embryos also have a dome-shaped head resulting from the imbalance between the development of a membranous roof and the endochondral base of the cranium (38). The roof of the cranium is least affected since it is comprised of membranous bones that develop without a cartilage intermediate. Ossification defects were much less severe when ablation is initiated at 12.5 dpc or 14.5 dpc. Our results indicate that GCV can cross the placenta, and embryonic cell ablation can be performed at a variety of different embryonic stages.
###end p 45
###begin p 46
###xml 75 78 75 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cre</italic>
###xml 110 119 110 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pu&#916;tk</italic>
###xml 171 173 167 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c10">10</xref>
###xml 489 491 485 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tk</italic>
###xml 541 548 537 544 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 484 488 <span type="species:ncbi:10298?0.9473684210526315">HSV1</span>
The use of a bigenic system allows the regulatory element (tissue-specific cre) and the effector element (the puDeltatk selector cassette) to be separated in the parents (10). Such separation prevents prodrug-mediated ablation of maternal tissues in pregnant females. In these experiments, the bigenic embryos exhibited severe ablation of proliferating chondrocytes, but there was no discernable effect on the pregnant females. To our knowledge, this is the first reported use of the HSV1 tk/GCV to ablate cells during embryonic development in vivo.
###end p 46
###begin p 47
###xml 23 25 23 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tk</italic>
###xml 101 103 101 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c40">40</xref>
###xml 104 106 104 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c42">42</xref>
###xml 218 225 218 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 227 232 227 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DTB-r</italic>
###xml 240 243 240 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ntr</italic>
###xml 402 404 402 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c43">43</xref>
###xml 405 407 405 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c44">44</xref>
###xml 425 428 425 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DTA</italic>
###xml 430 432 430 432 <italic xmlns:xlink="http://www.w3.org/1999/xlink">M2</italic>
###xml 437 444 437 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink">barnase</italic>
###xml 573 574 573 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c3">3</xref>
###xml 575 577 575 577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c45">45</xref>
###xml 578 580 578 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c46">46</xref>
###xml 639 648 639 644 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pu&#916;tk</italic>
###xml 794 797 790 793 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lox</italic>
###xml 806 809 802 805 <italic xmlns:xlink="http://www.w3.org/1999/xlink">frt</italic>
###xml 811 813 807 809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c47">47</xref>
###xml 814 816 810 812 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gnh158c48">48</xref>
###xml 853 856 849 852 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cre</italic>
###xml 18 22 <span type="species:ncbi:10298?0.9473684210526315">HSV1</span>
One limitation of HSV1 tk/GCV system is that GCV-mediated killing is limited to proliferating cells (40-42). Recently, several other conditional suicide gene/prodrug systems have been used in cell ablation experiments in vivo. DTB-r/DT and Ntr/CB1954 are two such systems in which killing is independent of cell proliferation, in principle these gene/prodrug systems can be used in place of HSVtk/GCV (43,44). Alternatively, DTA, M2 and barnase suicide genes can be used with inducible expression systems (such as the Tet-on/Tet-off system) to mediate conditional killing (3,45,46). It is possible to build effector strains similar to the puDeltatk selector described here, using different conditional suicide genes that can be activated by site-specific recombination systems, such as the Cre/loxP or Flp/frt (47,48). The increase in the repertoire of cre lines will expand the utility of the effector lines described here to different cell lineages.
###end p 47
###begin title 48
Figures and Tables
###end title 48
###begin p 49
###xml 17 26 17 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pu&#916;tk</italic>
###xml 66 67 62 63 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 80 89 76 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pu&#916;tk</italic>
###xml 144 153 136 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pu&#916;tk</italic>
###xml 341 342 329 330 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 365 366 353 354 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 444 453 432 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pu&#916;tk</italic>
###xml 583 592 567 572 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pu&#916;tk</italic>
###xml 209 214 <span type="species:ncbi:10090">mouse</span>
 Construction of puDeltatk selector and the experimental design. (A) The use of puDeltatk selector in conditional genetic ablation experiments. puDeltatk is activated in the Cre-expressing tissue of a bigenic mouse. Tissue-specific ablation can be performed in a temporally regulated manner by controlling the timing of GCV administration. (B) Targeting strategy. (C) Southern blot confirming targeting. Genomic DNA isolated from wild-type and puDeltatk selector embryonic stem cells, digested with HindIII and probed with a 5' external probe, showing the wild-type (7.1 kb) and the puDeltatk selector (6.8 kb) alleles.
###end p 49
###begin p 50
###xml 20 29 20 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pu&#916;tk</italic>
###xml 101 108 97 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col2Cre</italic>
###xml 110 119 106 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pu&#916;tk</italic>
###xml 149 150 141 142 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 170 179 162 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pu&#916;tk</italic>
###xml 213 214 201 202 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 355 356 343 344 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 444 451 432 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col2Cre</italic>
###xml 453 462 441 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pu&#916;tk</italic>
###xml 836 837 820 821 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 546 551 <span type="species:ncbi:10090">mouse</span>
 Cartilage-specific puDeltatk activation and GCV-mediated killing of proliferating chondrocytes in a Col2Cre, puDeltatk compound heterozygous male. (A) RT-PCR shows that puDeltatk is only activated in cartilage. (B) Schematic representation of the normal growth plate. R, resting zone; P, proliferating zone; H, hypertrophic zone; and O, ossifying zone. (C) BrdU immunohistochemistry reveals complete killing of proliferating chondrocytes in a Col2Cre, puDeltatk compound heterozygous male. In contrast to the tibia growth plate in the wild-type mouse, the tibia growth plate of the bigenic animal is totally disorganized. No obvious zones of chondrocytes representing the different stages of differentiation exist, instead an extended region comprised of enlarged, hypertrophic chondrocyte-like cells was observed. Arrows indicate BrdU+cells.
###end p 50
###begin p 51
###xml 101 102 101 102 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 206 213 206 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col2Cre</italic>
###xml 218 227 218 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pu&#916;tk</italic>
###xml 401 402 397 398 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 566 567 562 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 578 579 574 575 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 584 585 580 581 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D</bold>
###xml 743 747 739 743 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col2</italic>
###xml 752 761 748 753 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pu&#916;tk</italic>
###xml 113 117 <span type="species:ncbi:10090">mice</span>
###xml 228 232 <span type="species:ncbi:10090">mice</span>
###xml 246 251 <span type="species:ncbi:10090">mouse</span>
###xml 523 528 <span type="species:ncbi:10090">mouse</span>
###xml 533 537 <span type="species:ncbi:10090">mice</span>
###xml 695 700 <span type="species:ncbi:10090">mouse</span>
 GCV-mediated killing of proliferating chondrocytes blocks long bone growth but not mineralization. (A) X-ray of mice of all four different genotypes after a 6 week GCV treatment. In contrast to wild-type, Col2Cre and puDeltatk mice, the bigenic mouse is characterized by a shorter stature, dome-shaped rib cage, lower bone density and increased opacity in the long bone growth plates (arrow heads). (B) Measurement of total femur length at the end of the GCV treatment reveals a significant difference between the bigenic mouse and mice of all the other genotypes (P < 0.05). (C and D) Von Kossa staining reveals normal mineralization in the 'hypertrophic chondrocyte-like zone' in the bigenic mouse tibia growth plate: (C) wild type and (D) Col2Cre, puDeltatk. P, proliferating zone; H, hypertrophic zone; HL, hypertrophic-like zone.
###end p 51
###begin p 52
###xml 129 139 129 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col2&#945;1</italic>
###xml 144 161 140 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Co10&#945;1in situ</italic>
###xml 543 553 535 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col2&#945;1</italic>
###xml 610 621 598 605 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col10&#945;1</italic>
###xml 789 799 773 779 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col2&#945;1</italic>
###xml 803 814 783 790 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col10&#945;1</italic>
###xml 88 92 <span type="species:ncbi:10090">mice</span>
###xml 273 277 <span type="species:ncbi:10090">mice</span>
###xml 768 773 <span type="species:ncbi:10090">mouse</span>
 Abnormal hypertrophic chondrocyte differentiation in proliferating chondrocyte-ablated mice. Safranin O/fast green staining and Col2alpha1 and Co10alpha1in situ hybridization analyses (from the left to the right) of the tibia growth plates from wild-type (Wt) and bigenic mice before GCV treatment (2wk) after a 3 week GCV treatment (5wk) and after a 3 week recovery following a 3 week GCV treatment (8 week). Glycoproteins stained by safranin O are detected in both the wild-type and bigenic cartilage matrix after the 3 week GCV treatment. Col2alpha1 is normally expressed in proliferating chondrocytes and Col10alpha1 is expressed in hypertrophic chondrocytes. The enlarged hypertrophic 'chondrocyte-like cells' observed in the growth plate of the ablated bigenic mouse do not express Col2alpha1 or Col10alpha1. This analysis suggests that the hypertrophic 'chondrocyte-like cells' are neither proliferating chondrocytes nor terminally differentiated, fully func-tional hypertrophic chondrocytes. SO, safranin O; FG, fast green.
###end p 52
###begin p 53
###xml 67 68 67 68 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 187 188 187 188 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 205 206 205 206 <bold xmlns:xlink="http://www.w3.org/1999/xlink">E</bold>
###xml 227 228 227 228 <bold xmlns:xlink="http://www.w3.org/1999/xlink">F</bold>
###xml 262 263 262 263 <bold xmlns:xlink="http://www.w3.org/1999/xlink">H</bold>
###xml 314 315 314 315 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 317 318 317 318 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 320 321 320 321 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D</bold>
###xml 323 324 323 324 <bold xmlns:xlink="http://www.w3.org/1999/xlink">F</bold>
###xml 329 330 329 330 <bold xmlns:xlink="http://www.w3.org/1999/xlink">G</bold>
###xml 372 373 372 373 <bold xmlns:xlink="http://www.w3.org/1999/xlink">I</bold>
 GCV-mediated chondrocyte ablation at different embryonic stages. (A) Ablation in bigenic embryos initiated at 4.5 dpc results in dwarfism, megacephaly, multiple cranial-facial defects, (C) macroglossia, (E) umbilical hernia, (F) cleft palate (arrow heads) and (H) under ossified vertebrae. Wild-type littermates (A, B, D, F and G) are not affected by the GCV treatment. (I) GCV-mediated chondrocyte ablation initiated at different embryonic stages (4.5 dpc, 12.5 dpc and 14.5 dpc) results in skeletal developmental defects of different severities. Arrows indicate defects of different severity observed in vertebrae calcification and rib cage development. Earlier GCV treatment causes more severe skeletal defects.
###end p 53
###begin title 54
ACKNOWLEDGEMENTS
###end title 54
###begin p 55
###xml 141 145 141 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col2</italic>
###xml 149 153 <span type="species:ncbi:10090">mice</span>
We thank Dr Jim Lupski for his contributions to this study, Dr Richard R. Behringer and Dr Dmitry Ovchinnikov for useful suggestions and the Col2Cre mice, and Romain Dacquin for help in X-radiology. We also thank Sandra Rivera, Gabriele C. Schuster and Janis Wesley for technical assistance and Sarah Quakkelaar-Howard for help in preparing this manuscript. This work was supported by grants to AB from the NIH, National Cancer Institute.
###end p 55
###begin title 56
REFERENCES
###end title 56

